Evommune to present Phase 2a EVO301 atopic dermatitis data at EADV 2026 late-breaker session

By Public Technologies
  • Evommune set a late-breaking oral presentation of Phase 2a EVO301 data in moderate-to-severe atopic dermatitis at EADV 2026.
  • Results were already disclosed as positive top-line findings earlier in 2026; full data will be presented on Oct. 1 in Vienna.
  • Readout supports IL-18 inhibition as a potential new approach in atopic dermatitis, targeting broader inflammatory pathways than Th2-focused therapies.
  • Phase 2b dose-ranging study is expected to start in mid-2027, setting up the next development step for EVO301.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609231605BIZWIRE_USPR_____20260923_BW409038) on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.